the_newsbeagle writes: An FDA advisory committee met today to consider approving the NeuroAD device, which is supposed to help with the cognitive symptoms of Alzheimer’s disease. The device uses a combination of brain stimulation and cognitive training tasks to strengthen the neural circuits involved in language, memory, and other components of cognition. The treatment requires patients to come to the clinic daily for 1-hour sessions. Regulators in Israel and Europe have already approved the device. The CEO of the company behind the device, Neuronix, says that they’re not attempting to cure the underlying biological causes of Alzheimer’s. “We’re attempting to modify the course of the disease,” he says. The cognitive improvements last for up to a year, after which they fade away.
Read more of this story at Slashdot.